Healx, an AI-powered biotech company focused on rare diseases, has announced it will use a Sanofi compound to identify new disease indications through Healnet, its AI-driven drug discovery platform. Through this partnership, Sanofi will share data on a late-stage, discontinued compound that may be licensed out. Financial details were not disclosed. “Only 5% of rare diseases have an approved treatment,” noted Healx co-founder and CEO Tim Guilliams, Ph.D. “Our mission is to ensure no potential therapy is missed. This collaboration highlights our platform’s potential to uncover new indications, and we’re excited to partner with Sanofi to help patients in need.”
Healx’s technology suite rapidly identifies and develops new treatments for the 95% of rare diseases lacking approved therapies. Healx will not only use Healnet to analyze complex biological data for new indications but will also leverage its drug discovery and development expertise to provide Sanofi with AI-driven insights to support future development of the compound. Healnet incorporates generative AI to reveal connections between biological and chemical elements, potentially paving the way for new treatments.
“We’re pleased to see Healx apply AI in finding new indications for this compound, particularly in rare diseases,” said Michael Palladinetti, Sanofi’s global head of business development. “This partnership aligns with our commitment to innovative approaches that accelerate transformative therapy discovery, addressing unmet needs and offering new hope to patients.”
Click here to read the original news story.